We serve Dehydroisoandrosterone 3-acetate CAS:853-23-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Dehydroisoandrosterone 3-acetate
CAS.NO:853-23-6
Synonyms:
DEHYDROEPIANDROSTERONE-3-ACETATE
Dehydroepiandrosterone acetate
DHEAacetate(prasterone acetate)
DEHYDROISOANDROSTERONE ACETATE
Molecular Formula:C21H30O3
Molecular Weight:330.46100
Physical and Chemical Properties:
Density: 1.09 g / cm3
Boiling point: 434.8ºC at 760 mmHg
Melting point: 168-170ºC
Flash point: 188.1ºC
Refractive index: 1.54
Specification:
Appearance:White to almost white crystalline powder
Purity:≥98%
Loss on drying: ≤0.5%
Impurity: ≤0.5%
Packing:
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Abiraterone CAS:154229-19-3
Intermediates of Abiraterone acetate CAS:154229-18-2
Contact us for information like Dehydroisoandrosterone 3-acetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,DEHYDROISOANDROSTERONE ACETATE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,DHEAacetate(prasterone acetate) Use and application,Dehydroisoandrosterone 3-acetate technical grade,usp/ep/jp grade.
Related News: Fears over the continuing spread of coronavirus have also fueled resentment and discrimination. Some have become outcasts in their own country, shunned by hotels, neighbors and — in some areas — placed under controversial quarantine measures.Ethyl 2-BOC-aminothiazole-5-carboxylate manufacturer This part is mainly anti-tumor drugs, prostate drugs and certain hormone drugs.Methyl 4,4-dimethoxy-3-oxobutanoate supplier This part is mainly anti-tumor drugs, prostate drugs and certain hormone drugs.TRITYL ISOTHIOCYANATE vendor Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development.
